Risk and benefit of dual antiplatelet treatment among non-revascularized myocardial infarction patients in different age groups

European Heart Journal: Acute Cardiovascular Care

Volumn 6, Issue 6, 2017, Pages 511-521

  Juul, Nikolai ^a   Gislason, Gunnar ^a,b,c   Olesen, Jonas Bjerring ^a   Lamberts, Morten ^a   Hansen, Morten Lock ^a   Karasoy, Deniz ^a   Christiansen, Christine Benn ^a   Torp Pedersen, Christian ^a,d   Sorensen, Rikke ^a,e  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d AALBORG UNIVERSITY   (Denmark)

^e BISPEBJERG HOSPITAL   (Denmark)

Author keywords

Age groups; Aspirin; cardiovascular; clopidogrel; epidemiology; haemorrhage; myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PRASUGREL; PROTON PUMP INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TICAGRELOR; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

AGE; AGED; ALL CAUSE MORTALITY; ARTICLE; BLEEDING; BRAIN ISCHEMIA; COHORT ANALYSIS; COMORBIDITY ASSESSMENT; DRUG THERAPY; DUAL ANTIPLATELET THERAPY; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; REGISTER; RISK BENEFIT ANALYSIS; AGE DISTRIBUTION; ANALOGS AND DERIVATIVES; CAUSE OF DEATH; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DENMARK; FOLLOW UP; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; PROPENSITY SCORE; RETROSPECTIVE STUDY; SURVIVAL RATE; TIME FACTOR; TREATMENT OUTCOME; TRENDS;

AGE DISTRIBUTION; AGE FACTORS; AGED; ASPIRIN; CAUSE OF DEATH; DENMARK; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85049035691     PISSN: 20488726     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872614538848     Document Type: Article

References (28)

1. Yusuf S, Zhao F, Mehta SR. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; Vol 345 494–502.
2. Steg PG, James SK, Atar D. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33: 2569–2619, http://www.ncbi.nlm.nih.gov/pubmed/22922416 (2012).
3. Chen ZM, Jiang LX, Chen YP. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366: 1607–1621, http://www.ncbi.nlm.nih.gov/pubmed/16271642 (2005).
4. Lewis HD, Davis JW, Archibald DG. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 309: 396–403, http://www.ncbi.nlm.nih.gov/pubmed/6135989 (2014).
5. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 2: 349–360, http://www.ncbi.nlm.nih.gov/pubmed/2899772 (1988).
6. Anderson JL, Adams CD, Antman EM. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol 50: e1–e157, http://www.ncbi.nlm.nih.gov/pubmed/17692738 (2007).
7. Bassand J-P, Hamm CW, Ardissino D. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 28: 1598–1660, http://www.ncbi.nlm.nih.gov/pubmed/17569677 (2007).
8. Sørensen R, Gislason GH, Fosbøl EL. Initiation and persistence with clopidogrel treatment after acute myocardial infarction: a nationwide study. Br J Clin Pharmacol 66: 875–884, http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2675763&tool=pmcentrez&rendertype=abstract (2008).
9. Yusuf S, Islam S, Chow CK. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378: 1231–1243, http://www.ncbi.nlm.nih.gov/pubmed/21872920 (2011).
10. Nauta ST, Deckers JW, Akkerhuis KM. Age-dependent care and long-term (20 year) mortality of 14,434 myocardial infarction patients: changes from 1985 to 2008. Int J Cardiol 167: 693–697, http://www.ncbi.nlm.nih.gov/pubmed/22465352 (2013).
11. Sørensen R, Hansen ML, Abildstrom SZ. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 374: 1967–1974, http://www.ncbi.nlm.nih.gov/pubmed/20006130 (2009).
12. Rao SV, O’Grady K, Pieper KS. Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96: 1200–1206, http://www.ncbi.nlm.nih.gov/pubmed/16253582 (2005).
13. D’Hoore W, Sicotte C, Tilquin C. Risk adjustment in outcome assessment: the Charlson comorbidity index. Methods Inf Med 32: 382–387, http://www.ncbi.nlm.nih.gov/pubmed/8295545 (1993).
14. Rao SV. Bleeding as a predictor of mortality risk. Rev Cardiovasc Med 7 (Suppl. 3): S12–S8, http://www.ncbi.nlm.nih.gov/pubmed/17224879 (2006).
15. Medina HM, Cannon CP, Zhao X. Quality of acute myocardial infarction care and outcomes in 33,997 patients aged 80 years or older: findings from Get With The Guidelines-Coronary Artery Disease (GWTG-CAD). Am Heart J 162: 283–290.e2, http://www.ncbi.nlm.nih.gov/pubmed/21835289 (2011).
16. http://nowbase.org/Publikationer/~/media/Projekt%20sites/Nowbase/Publikationer/NCSP/NCSP%201_14.ashx (accessed 27 May 2014)
17. Madsen M, Davidsen M, Rasmussen S. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 56: 124–130, http://www.ncbi.nlm.nih.gov/pubmed/12654406 (2003).
18. Greedy Match macro for SAS. Mayo Clinic College of Medicine. http://www.mayo.edu/research/departments-divisions/department-health-sciences-research/division-biomedical-statistics-informatics/software/locally-written-sas-macros (2003, accessed 10 November 2013)
19. Sørensen R, Abildstrøm SZ, Hansen PR. Efficacy of post-operative clopidogrel treatment in patients revascularized with coronary artery bypass grafting after myocardial infarction. J Am Coll Cardiol 57: 1202–1209, http://www.ncbi.nlm.nih.gov/pubmed/21371637 (2011).
20. Bonde L, Sorensen R, Fosbøl EL. Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study. J Am Coll Cardiol 55: 1300–1307, http://www.ncbi.nlm.nih.gov/pubmed/20338489 (2010, accessed 15 January 2014).
21. Held C, Asenblad N, Bassand JP. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 57: 672–684, http://www.ncbi.nlm.nih.gov/pubmed/21194870 (2011, accessed 9 April 2014).
22. Wiviott SD, Braunwald E, McCabe CH. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 357: 2001–2015, http://www.ncbi.nlm.nih.gov/pubmed/17982182 (2007, accessed 24 March 2014).
23. Roe MT, Armstrong PW, Fox K. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med 367: 1297–1309, http://www.ncbi.nlm.nih.gov/pubmed/22920930 (2013, accessed 23 January 2014).
24. Wallentin L, Becker RC, Budaj A. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 361: 1045–1057, http://www.ncbi.nlm.nih.gov/pubmed/19717846 (2009, accessed 19 March 2014).
25. Tricoci P, Roe MT, Mulgund J. Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital discharge. Arch Intern Med 166: 806–811, http://www.ncbi.nlm.nih.gov/pubmed/16606819 (2006, accessed 9 April 2014).
26. Lamberts M, Olesen JB, Ruwald MH. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 126: 1185–1193, http://www.ncbi.nlm.nih.gov/pubmed/22869839 (2012, accessed 15 January 2014).
27. Cay S, Cagirci G, Aydogdu S. Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. Drugs Aging 28: 119–129, http://www.ncbi.nlm.nih.gov/pubmed/21275437 (2011, accessed 9 April 2014).
28. Gaist D, Sørensen HT, Hallas J. The Danish prescription registries. Dan Med Bull 44: 445–448, http://www.ncbi.nlm.nih.gov/pubmed/9377907 (1997, accessed 9 April 2014).